OvaScience Announces Global Healthcare Strategist Marc Kozin Joins Company's Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
(NASDAQ:OVAS), a life sciences company focused on the discovery,
development and commercialization of new treatments for infertility,
announced today the appointment of Marc Kozin, former President of
L.E.K. Consulting's North American practice, to the Company's Board of
"Marc has been advising healthcare companies on the growth of their
businesses, technology platforms, and product lines for close to 30
years," said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of
OvaScience. "His experience helping companies develop global commercial
strategies will guide us as we make AUGMENT available in IVF clinics
outside the U.S. this year."
"OvaScience's technology has the potential to improve female fertility,
and the value of its EggPCSM platform could have broader
applications in other areas including human and animal health," said Mr.
Kozin. "I look forward to working with OvaScience to get innovative and
much needed products to patients as soon as possible."
Mr. Kozin has nearly 30 years of experience in corporate and business
unit strategy consulting, merger and acquisition advisory services, and
value management both domestically and internationally. Mr. Kozin served
as president of the North American practice of L.E.K., a global strategy
consulting firm, for 15 years and has been a Senior Advisor to L.E.K.
since July 2011. He currently serves as a member of the Board of
Directors of UFP Technologies, Inc., DYAX Corp., Endocyte, Inc., and
three privately-held companies. He also serves on the strategic advisory
board for Healthcare Royalty Partners, a global healthcare investment
firm. Mr. Kozin holds a B.A., with distinction, in economics from Duke
University and an M.B.A., with distinction, from The Wharton School,
University of Pennsylvania.
Mr. Kozin will replace Jonathan Tilly, Ph.D., a scientific co-founder of
OvaScience who was recently appointed as Chair of the Department of
Biology at Northeastern University. Dr. Tilly will continue to serve as
a member of OvaScience's Scientific Advisory Board.
OvaScience (NASDAQ:OVAS) is a life sciences company focused on the
discovery, development and commercialization of new treatments for
infertility. The Company's patented technology is based on the discovery
of egg precursor cells (EggPCSM), which are found in the
ovaries. By applying proprietary technology to identify and purify
EggPCs, OvaScience is developing potential next generation in vitro fertilization
(IVF) technologies. The Company currently has two product candidates in
development: OvaTureSM, which seeks to create mature
fertilizable eggs from a woman's own EggPCs without the need for hormone
injections, and AUGMENTSM, which aims to improve egg quality
and increase the success of IVF. OvaScience's team of scientists,
physicians and advisers includes recognized leaders in the field of
reproductive medicine. For more information, please visit www.ovascience.com
and connect with us on Twitter
This press release includes forward-looking statements about the
prospects for the Company's technology in addressing female infertility,
the Company's strategy, future plans and prospects, including statements
regarding the development of the Company's product candidates, including
AUGMENT, and the Company's plan to make AUGMENT available in select
countries outside of the United States. Any statements in this release
about our strategy, plans, prospects and future expectations, financial
position and operations, and other statements containing the words
"anticipate," "believe," "estimate," "expect," "intend," "may," "plan,"
"predict," "project," "target," "aim," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including risks related to: our expectations regarding the regulatory
approvals required for AUGMENT outside of the United States; the science
underlying our two product candidates (AUGMENT and OvaTure), which is
unproven; our ability to obtain, maintain and protect intellectual
property utilized by our products;our ability to obtain
additional funding to support our activities; our dependence on third
parties; the successful development of, and ability to obtain regulatory
approval for, our product candidates; our ability to commercialize our
product candidates, including AUGMENT, on the timeline we expect, if at
all; competition from others; and our short operating history; as well
as those risks more fully discussed in the "Risk Factors" section of our
most recently filed Quarterly Report on Form 10-Q or Annual Report on
Form 10-K. The forward-looking statements contained in this press
release reflect our current views with respect to future events.We
anticipate that subsequent events and developments will cause our views
to change. However, while we may elect to update these forward-looking
statements in the future, we specifically disclaim any obligation to do
so. These forward-looking statements should not be relied upon as
representing our view as of any date subsequent to the date hereof.